Posted by Michael Wonder on 19 Apr 2018
Xultophy approved in Canada for the treatment of adults with type 2 diabetes
18 April 2018 - Once-daily Xultophy has been shown to help patients achieve blood glucose targets.
Novo Nordisk announced today that Health Canada has approved Xultophy as an adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily), do not provide adequate glycemic control.
The approval of Xultophy is based on efficacy and safety data from the DUAL (Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes) clinical development program. In three DUAL trials involving 1,393 adults with type 2 diabetes, patients who were inadequately controlled on liraglutide or basal insulin therapy and switched to Xultophy achieved significant reductions in HbA1c.1 For adults uncontrolled on basal insulin, Xultophy demonstrated reductions in HbA1c from baseline of 1.81% (vs insulin glargine) and 1.90% (vs basal insulin therapies).
